ABSTRACT
Introduction
Primary cutaneous T cell lymphomas (CTCL) are a heterogenous group of non-Hodgkin lymphomas derived from skin-homing T cells. These include mycosis fungoides and its leukemic variant Sezary syndrome, as well as the CD30+ lymphoproliferative disorders.
Areas Covered
In this review, we provide a summary of the current literature on CTCL, with a focus on the immunopathogenesis and treatment of mycosis fungoides and Sezary syndrome.
Expert Opinion
Recent advances in immunology have provided new insights into the biology of malignant T cells. This in turn has led to the development of new therapies that modulate the immune system to facilitate tumor clearance or target specific aspects of tumor biology.
Article highlights
Cutaneous T cell lymphoma (CTCL) is a malignancy of skin-homing T cells that can range from skin-limited disease to leukemic involvement (Sezary syndrome)
CTCL results in a number of immune derangements that subvert the endogenous anti-tumor response
Early-stage CTCL is often managed with topical therapies whereas management of advanced CTCL often includes systemic therapies that specifically target aspects of tumor biology and augment anti-tumor immune responses
Research is ongoing to identify additional therapies and identify potential biomarkers of treatment response
Declaration of interest
A Rook is a lecturer for Mallinckrodt and a consultant for TLR Bio. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.